

# Hydroxychloroquine for Treatment of COVID-19 Patients: a Systematic Review and Meta-Analysis of Randomized Controlled Trials

**Vinícius Y Moraes**

Hospital Israelita Albert Einstein <https://orcid.org/0000-0002-4933-4007>

**Alexandre R Marra**

Hospital Israelita Albert Einstein

**Leandro L Matos**

Hospital Israelita Albert Einstein

**Ary Serpa Neto**

Hospital Israelita Albert Einstein

**Luiz Vicente Rizzo**

Hospital Israelita Albert Einstein

**Miguel Cendoroglo Neto**

Hospital Israelita Albert Einstein

**Mário Lenza** (✉ [vinicius.moraes@einstein.br](mailto:vinicius.moraes@einstein.br))

1. Instituto Israelita de Ensino e Pesquisa Albert Einstein, Hospital Israelita Albert Einstein

---

## Research

**Keywords:** Hydroxychloroquine, COVID-19, treatment, randomized controlled trials, systematic review.

**Posted Date:** June 16th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-603673/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

## Abstract

**Background:** We performed a systematic review of the literature and meta-analysis on the efficacy and safety of hydroxychloroquine to treat coronavirus disease 2019 (COVID-19) patients.

**Methods:** We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and LILACS (2019 to March 2021) for patients aged 18 years or older, who had COVID-19 and were treated with hydroxychloroquine *versus* placebo or standard of care. We also searched the WHO Clinical Trials Registry for ongoing and recently completed studies, and the reference lists of selected articles and reviews for possible relevant studies, with no restrictions regarding language or publication status. Random-effects models were used to obtain pooled mean differences of treatment effect on mortality, and serious adverse effects between hydroxychloroquine (HCQ) and the control group (standard of care or placebo); heterogeneity was assessed using the  $I^2$  and the Cochran's Q statistic.

**Results:** Nine studies met the inclusion criteria and were included in the meta-analysis. There was no significant difference in mortality rate between patients treated with HCQ compared to standard of care or placebo (16.7% vs. 18.5%; pooled risk ratio 1.09; 95%CI: 0.99-1.19). Also, the rate of serious adverse effects was similar between both groups, HCQ and control (3.7% vs. 2.9%; pooled risk ratio 1.22; 95%CI: 0.76-1.96). **Conclusion:** Hydroxychloroquine is not efficacious in reducing mortality of COVID-19 patients.

**Systematic review registration:** Prospero database, registration number: CRD42020197070.

## Background

Hydroxychloroquine (HCQ) has received worldwide attention as a potential treatment for coronavirus disease 2019 (COVID-19) because of positive results from small studies [1,2]. Since then, HCQ, combined or not with azithromycin, has been considered as a possible therapeutic agent for patients with COVID-19 [2,3]. To date, there are very few specific treatments for COVID-19 patients [4,5]. The vast majority of studies assessing treatments for these patients were small clinical studies, which were not acceptable, even in a pandemic, due to their design and characteristics (e.g., non-randomized, underpowered, and/or open label). In addition, the medical principle "first do not harm" should be one of the first principles in any clinical study [6].

There are several reports and studies on the potential effect of HCQ on inhibiting the action of various viruses, such as other coronaviruses (SARS-CoV-1, MERS-CoV), Ebola virus, HIV, influenza virus (H1N1) and hepatitis B and C viruses [7]. However, there is a huge difference between what happens *in vitro* and *in vivo* [8]. Moreover, the association of HCQ and other antimicrobial therapy, and the potential adverse events, have not been fully understood yet. We aimed to perform a systematic review of the literature and a meta-analysis and evaluate the effects of hydroxychloroquine prescription to treat adult COVID-19 patients, considering mortality and prevention of serious adverse events.

## Method

The systematic review of the literature was conducted in line with PRISMA guidelines and Cochrane handbook [9,10], and was registered at Prospero database (CRD42020197070) [11]. It included all randomized controlled trials (RCTs) published, which assessed COVID-19 patients aged 18 years or older, who were treated with chloroquine or hydroxychloroquine, at any dose, and compared to a control group that received other experimental antiviral treatment, supportive treatment or placebo. We excluded prevention or post-exposure prophylaxis studies.

### Search strategy

We searched the Cochrane Central Register of Controlled Trials (CENTRAL; in The Cochrane Library current issue), MEDLINE, EMBASE, and LILACS (2019 to March 2021). We also searched the WHO Clinical Trials Registry for ongoing and recently completed studies, and the reference lists of selected articles and reviews for possible relevant studies, with no restrictions regarding language or publication status.

In MEDLINE (PubMed), we combined the subject-specific search (((("coronavirus"[mesh terms]) or (coronavirus\*[title/abstract] or coronavirus\*[title/abstract] or coronavirinae\*[title/abstract] or coronavirus\*[title/abstract] or coronavirus\*[title/abstract] or wuhan\*[title/abstract] or hubei\*[title/abstract] or huaian\*[title/abstract] or "2019-ncov"[title/abstract] or 2019ncov[title/abstract] or ncov2019[title/abstract] or "ncov-2019"[title/abstract] or "covid-19"[title/abstract] or covid19[title/abstract] or "hcov-19"[title/abstract] or hcov19[title/abstract] or cov[title/abstract] or "2019 novel\*" [title/abstract] or ncov[title/abstract] or "n-cov"[title/abstract] or "sars-cov-2"[title/abstract] or "sarscov-2"[title/abstract] or "sarscov2"[title/abstract] or "sars-cov2"[title/abstract] or "sars-cov-19"[title/abstract] or ncorona\*[title/abstract])) AND ((((((Hydroxychloroquine[MeSH Terms]) OR (Chloroquine[MeSH Terms])) OR (chloroquin\*[Title/Abstract]) OR (Hydroxychloroquin\*[Title/Abstract]) OR (Oxychloroquin\*[Title/Abstract]) OR (antimalaria\*[Title/Abstract]) OR (anti-malaria\*[Title/Abstract])))). Search strategies were adapted to The Cochrane Library (Wiley InterScience), EMBASE (Ovid Web), and LILACS.

### Selection of studies

Two authors (ML and VYM) independently identified and selected potentially eligible studies for inclusion in the review. Any disagreements were resolved by discussion and consensus. A third author was included in the discussion, if needed. The review authors were not blinded to the journal or authors.

### Data extraction

Two authors (ML and LLM) independently extracted the following data using a specific extraction form: characteristics of the study including study design, duration of the study, if the protocol was published before recruitment of patients, funding sources, and details of trial registration; characteristics of the study including place of study, number of participants assigned, number of participants assessed, inclusion criteria, exclusion criteria and age; characteristics of the

study interventions including timing and type of intervention and control, and any co-interventions; characteristics of the study outcomes including the length of follow-up, loss to follow-up, and outcome measures; and the methodological domains looking for risk of bias. Any disagreements were resolved by discussion.

The risk of bias of the included studies was assessed by two independent authors (ML and VYM). As recommended by The Cochrane Collaboration Risk of Bias tool [12], we assessed the following domains: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective reporting; and other bias (e.g., major baseline imbalance). Each of these criteria was evaluated using low risk of bias; high risk of bias; and unclear (either lack of information or uncertainty over potential for bias). Disagreements between authors regarding the risk of bias for the domains were resolved by discussion.

### Outcomes

The primary outcome was all-cause mortality. As second outcome, we evaluated serious adverse events of HCQ treatment (life-threatening or requiring hospitalization or adverse events that resulted in discontinuation of treatment). Other outcomes could not be assessed due to substantial heterogeneity between measurements and outcomes of the included studies.

### Statistical analysis

We combined the results of the included trials by performing a meta-analysis, using the Review Manager version 5.0 (The Cochrane Collaboration), and a p-value less than 0.05 was considered significant [13]. For rate comparisons, we calculated the risk ratio (RR) with a 95% confidence interval (95%CI) for individual studies. We pooled similar studies using a random-effects model, according to the Mantel and Haenszel method for estimating the RR and its 95%CI, and pooled data are shown in forest plots.

The unit of randomization for all trials included was the individual participant of study. There were no unit of analysis issues when considering cluster-randomized trials. Where appropriate, problems of unit of analysis with multiple reporting of outcomes, such as different follow-up times were solved by presenting these separately.

The presence of heterogeneity among the studies was estimated by the Cochran's Q statistic and measured by the  $I^2$  value, and heterogeneity was considered present for  $I^2 > 50\%$ . Data from the systematic review were grouped, and the weighted average was calculated as the studies' summary measure. Funnel plots were obtained to estimate the publication bias.

### Assessment of quality of evidence and 'Summary of findings' table

The GRADE approach was used to assess the quality of evidence related to two outcomes – mortality and serious adverse events [14]. Quality of evidence was categorized as 'high', 'moderate', 'low', or 'very low', depending on the presence and extent of five factors: risk of bias, inconsistency of effect, indirectness, imprecision, and publication bias.

The main results of the use of hydroxychloroquine to treat participants with COVID-19 are presented in a 'Summary of findings' table, which provides key information concerning quality of evidence, magnitude of effect of the interventions examined, and the sum of available data on the main outcomes.

## Results

### Results of the search

The searches for this review identified a total of 3,014 articles for analysis, and 44 reports of potentially eligible studies, for which we obtained full reports, whenever possible. Of these, nine studies [15-23] were included, and eight, excluded [24-31]. The flowchart of article selection is available in Figure 1.

The number of subjects per study ranged from 19 to 1,561 participants in the treatment group, and from 11 to 3,155 in the control group. All studies included evaluated only hydroxychloroquine in the intervention arm, as described in Table 1.

### Quality assessment

Overall quality of the trials was compatible with COVID-19 pandemic scenario and most fulfilled the expected standards. One important caveat to be pinpointed is the fact that most of the trials were designed to produce a more pragmatic than explanatory evidence (real world evidence). Trials failed most at blinding participants and personnel, and we had some special concerns regarding some underpowered trials, which we downgraded to the "other bias" section. Some other concerns are related to lack of standardization to define adverse effects and their stratification. These criteria had substantially varied between trials. Figure 2 summarizes the main aspects regarding risk or quality assessment.

### Effects of interventions

Table 2 shows the summary of findings for the main comparisons of hydroxychloroquine to treat participants with COVID-19. The primary comparison in this review was hydroxychloroquine *versus* standard of care in management of COVID-19 patients. We presented our results for two endpoints: mortality and serious adverse events.

### Mortality

Hydroxychloroquine did not significantly reduce the mortality rate of COVID-19 when compared to standard of care (control group) (16.7% vs. 18.5%; risk ratio 1.09; 95%CI: 0.99-1.19), with no heterogeneity across the studies ( $I^2=0\%$ ), as demonstrated in Figure 3.

#### *Serious adverse events*

The rate of serious adverse effects was similar in both groups HCQ and control (3.7% vs. 2.9%; risk ratio 1.22; 95%CI: 0.976-1.96), with low heterogeneity across the studies ( $I^2=28\%$ ), as shown in Figure 4.

#### Reporting bias

A robust analysis of potential publication bias was not possible due to the small number of studies published in the specific literature. However, a potential publication bias for mortality was not identified when evaluating the funnel plot (Figure 5A). And the relation with serious adverse events (Figure 5B) could not be well established.

## Discussion

In the present systematic review of the literature and meta-analysis including nine randomized clinical trials, and 8,303 COVID-19 patients, there was no significant reduction in mortality when hydroxychloroquine was used as treatment. Moreover, the drug was not related to an increase in serious adverse events.

Not all studies included provided evidence for all outcomes, and the quality of evidence for important outcomes was low for mortality, and very low for adverse events.

A growing number of hospitals reconsidered treating COVID-19 patients with HCQ after the first publications, in mid-2020's [20]. However, HCQ has received much attention and been very widely employed to treat COVID-19 patients, despite the absence of any good evidence. Altogether, these findings support the absence of evidence on the use of HCQ to treat COVID-19 patients. Similarly, other therapeutical options considered should be investigated through well-powered properly designed RCTs.

In clinical trials, the action of the drug studied is expected to bring some benefits for human beings, in terms of clinical outcomes. In other words, we need a drug that allows for longer survival, and avoid deaths. Furthermore, no adverse events are desired or, if not possible, just a few. All of these clinical outcomes should be evaluated in a clinical study. For drug evaluation, randomized studies are required. The good news is there are many ongoing studies on COVID-19. Based on this approach, our systematic review and meta-analysis only included RCTs. We also opted to not include non-randomized, quasi-experimental studies, which aim to demonstrate causality between an intervention and an outcome, and encompass a broad range of non-randomized intervention studies. These designs are frequently used when it is not logistically feasible or ethical to conduct a RCT [32]. However, this is not the case for the COVID-19 pandemic. For COVID-19 patients, there is still no treatment capable of acting on the SARS-CoV-2 virus, and that is why we chose to seek the best evidence, by using only RCTs in our meta-analysis. We also conducted a systematic review of the literature after one year of the COVID-19 pandemic, to have enough time for RCTs to be published. Previous reported systematic reviews and meta-analyses evaluated safety of hydroxychloroquine in COVID-19, and focused only on adverse events [33], or included just a small portion of these RCTs [34], or also included unpublished clinical trial [35]. Differently from them, we focused on investigating studies that evaluated mortality as outcome, reported severe adverse events associated to COVID-19, and only published RCTs from peer-review manuscripts were included.

The literature presents some misleading information on *in vitro* data and clinical trials. Hydroxychloroquine and chloroquine were shown to prevent viral infection in cell-culture systems; nonetheless, clinical trials in humans did not detect a significant improvement in COVID-19 patients treated with these drugs. Studies reported that hydroxychloroquine and chloroquine slightly decreased the viability of Vero, TMPRSS2-expressing Vero and Calu-3 cells when introduced at the highest concentration. Hydroxychloroquine and chloroquine could block S-driven entry, but this inhibition is cell-line-dependent, and efficient inhibition has not been observed in TMPRSS2+ lung cells [35,36].

Our analysis has some limitations. The interpretation of these findings requires caution due to substantial differences among the studies included. In addition, the population of these studies is heterogeneous, comprising hospitalized and non-hospitalized patients. It is important to emphasize this aspect because when we searched the number of deaths due to COVID-19, we attributed it as mortality in our meta-analysis but with no real-time definition of it. For analysis of serious adverse events, each study adopted a different definition. Moreover, the HCQ dose criteria were different among studies. Most of them considered a loading dose, and maintenance doses varying from 400-800 mg/day; and total treatment time was also diverse. Considering sample size, the RECOVERY study [20] had a large sample (weight of more than 80% in the compilation of our meta-analysis for mortality), followed by the WHO Solidarity Trial Consortium, by Pan *et al.* (weight of more than 10%) [19]; both studies indicated no mortality benefit for HCQ use against COVID-19. Even including only RCTs in our meta-analysis, just two studies were double-blinded [21, 22]. Double-blinded trials are thought to produce objective results since the expectations of researchers and participants about the experimental treatment, such as HCQ, do not affect the outcome. Although it does not reflect the real-life circumstances, and this may be one of the main reasons for most of these studies not adopting double-blind methods. Another important point was publication bias could not be properly addressed, since the number of included studies was small.

In conclusion, our systematic review and meta-analysis, exclusively with published randomized controlled trials, found treatment with hydroxychloroquine is not efficacious to reduce mortality of COVID-19 patients.

## Declarations

## Acknowledgements

We thank Mrs. Suzana Gontijo for language editing services and also Celso Dias in the support for manuscript search and selection.

## Funding

No external sources of funding

## Authors' contributions

AM, ASN, LVR, MCN, ML conceived and designed the study. AM, ML, ASN conducted initial background research. VYM, LML, ML selected and appraised the articles, extracted data and assessed quality of evidence. ML and AM resolved the disagreements. LML and VYM synthesized the data. VYM and AM wrote the first draft of the manuscript. ASR and AM interpreted the data and contributed to the writing of the final version of the manuscript. ML, LVN and MCN made the final amendments prior to submission. All the authors declare no conflict of interest regarding to this research.

## References

1. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? *Int J Antimicrob Agents*. 2020 May;55(5):105938.
2. Meo SA, Klonoff DC, Akram J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. *Eur Rev Med Pharmacol Sci*. 2020 Apr;24(8):4539-4547.
3. Fan J, Zhang X, Liu J, Yang Y, Zheng N, Liu Q, et al. Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019. *Clin Infect Dis*. 2020 Dec 15;71(12):3232-3236.
4. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med*. 2020 Nov 5;383(19):1813-1826.
5. Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet*. 2020 May 30;395(10238):1695-1704.
6. Institute of Medicine. 2000. *To Err Is Human: Building a Safer Health System*. Washington, DC: The National Academies Press. <https://doi.org/10.17226/9728>.
7. Al-Bari MAA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. *Pharmacol Res Perspect*. 2017 Jan 23;5(1):e00293.
8. Fan J, Zhang X, Liu J, Yang Y, Zheng N, Liu Q, et al. Connecting Hydroxychloroquine In Vitro Antiviral Activity to In Vivo Concentration for Prediction of Antiviral Effect: A Critical Step in Treating Patients With Coronavirus Disease 2019. *Clin Infect Dis*. 2020 Dec 15;71(12):3232-3236.
9. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement [published correction appears in *Int J Surg*. 2010;8(8):658]. *Int J Surg*. 2010;8(5):336-341. doi:10.1016/j.ijsu.2010.02.007
10. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.0 (updated July 2019). Cochrane, 2019. Available from [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
11. Lenza M, Luongo de Matos L, Marra AR, Serpa Neto A, Rizzo LV. Chloroquine or hydroxychloroquine for treat and prevent participants with COVID-19. PROSPERO 2020 CRD42020197070 Available from: [https://www.crd.york.ac.uk/prospero/display\\_record.php?ID=CRD42020197070](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020197070)
12. Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.0 (updated July 2019). Cochrane, 2019. Available from: [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
13. Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. Available from: <http://tech.cochrane.org/home>
14. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from: [training.handbook.cochrane.org](http://training.handbook.cochrane.org).
15. Abd-Elsalam S, Esmail ES, Khalaf M, Abdo EF, Medhat MA, Abd El Ghafar MS, et al. Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. *Am J Trop Med Hyg*. 2020;103(4):1635-1639. doi: 10.4269/ajtmh.20-0873. PMID: 32828135; PMCID: PMC7543820.
16. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Coalition Covid-19 Brazil I Investigators. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *N Engl J Med*. 2020 Nov 19;383(21):2041-2052. doi: 10.1056/NEJMoa2019014. Epub 2020 Jul 23. Erratum in: *N Engl J Med*. 2020 Nov 19;383(21):e119. PMID: 32706953; PMCID: PMC7397242.
17. Chen L, Zhang Z, Fu J, Feng Z, Zhang S, Han Q, et al. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study. doi:10.1101/2020.06.19.20136093. PPR:PPR178581.
18. Lyngbakken MN, Berdal JE, Eskesen A, Kvale D, Olsen IC, Rueegg CS, et al. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. *Nat Commun*. 2020 Oct 20;11(1):5284. doi: 10.1038/s41467-020-19056-6. PMID: 33082342; PMCID: PMC7576792.
19. WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 2021 Feb 11;384(6):497-511.

20. RECOVERY Collaborative Group, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* 2020 Nov 19;383(21):2030-2040.
21. Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. *JAMA* 2020 Dec 1;324(21):2165-2176.
22. Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. *Ann Intern Med* 2020 Oct 20;173(8):623-631. doi: 10.7326/M20-4207. Epub 2020 Jul 16. Erratum in: *Ann Intern Med* 2021 Mar;174(3):435.
23. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ*. 2020 May 14;369:m1849. doi: 10.1136/bmj.m1849. PMID: 32409561; PMCID: PMC7221473.
24. Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al. COALITION COVID-19 Brazil II Investigators. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. *Lancet*. 2020 Oct 3;396(10256):959-967. doi: 10.1016/S0140-6736(20)31862-6. Epub 2020 Sep 5. PMID: 32896292; PMCID: PMC7836431.
25. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. CloroCovid-19 Team. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA Netw Open*. 2020 Apr 24;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857. PMID: 32330277.
26. Sekhavati E, Jafari F, SeyedAlinaghi S, Jamalimoghaddamsiahkali S, Sadr S, Tabarestani M, et al. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. *Int J Antimicrob Agents*. 2020 Oct;56(4):106143. doi: 10.1016/j.ijantimicag.2020.106143. Epub 2020 Aug 25. PMID: 32853672; PMCID: PMC7445147.
27. Scarsi M, Piantoni S, Colombo E, Airò P, Richini D, Miclini M, et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. *Ann Rheum Dis*. 2020 Oct;79(10):1286-1289. doi: 10.1136/annrheumdis-2020-217712. Epub 2020 Jul 30. PMID: 32732245; PMCID: PMC7509521.
28. Mitjà O, Corbacho-Monné M, Ubals M, Tebe C, Peñafiel J, Tobias A, et al. BCN PEP-CoV-2 RESEARCH GROUP. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. *Clin Infect Dis*. 2020 Jul 16:ciaa1009. doi: 10.1093/cid/ciaa1009. Epub ahead of print. PMID: 32674126; PMCID: PMC7454406.
29. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *N Engl J Med*. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3. PMID: 32492293; PMCID: PMC7289276.
30. Pastick KA, Okafor EC, Wang F, Lofgren SM, Skipper CP, Nicol MR, et al. Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). *Open Forum Infect Dis*. 2020 Apr 15;7(4):ofaa130. doi: 10.1093/ofid/ofaa130. PMID: 32363212; PMCID: PMC7184359.
31. Radha Rajasingham, Ananta S Bangdiwala, Melanie R Nicol, Caleb P Skipper, Katelyn A Pastick, Margaret L Axelrod, et al. COVID PREP team, Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial, *Clinical Infectious Diseases*, 2020 *Clin Infect Dis*. 2021 Jun 1;72(11):e835-e843., <https://doi.org/10.1093/cid/ciaa1571>.
32. Harris AD, Lautenbach E, Perencevich E. A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance. *Clin Infect Dis* 2005; 41:77-82.
33. Chen C, Pan K, Wu B, Li X, Chen Z, Xu Q, et al. Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials. *Eur J Clin Pharmacol* 2021 Jan;77(1):13-24.
34. Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. *BMJ* 2020 Jul 30;370:m2980. doi: 10.1136/bmj.m2980.
35. Axfors C, Schmitt AM, Janiaud P, Van't Hooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. *Nat Commun* 2021 Apr 15;12(1):2349. doi: 10.1038/s41467-021-22446-z. Erratum in: *Nat Commun*. 2021 May 14;12(1):3001.
36. Ou T, Mou H, Zhang L, Ojha A, Choe H, Farzan M. Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2. *PLoS Pathog*. 2021 Jan 19;17(1):e1009212.
37. Hoffmann M, Mösbauer K, Hofmann-Winkler H, Kaul A, Kleine-Weber H, Krüger N, et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. *Nature*. 2020 Sep;585(7826):588-590.

## Tables

Table 1  
Main characteristics of the included studies.

Study ID	Country	Site	Drug	HCQ regimens	Control	Age (years)	Subjects on HCQ	Subjects on control	Diagnosis	RT-PCR	Covid, Mild	C n
Abd-Elsalam, 2020 [15]	Egypt	Hospital	HCQ	800 mg (1 day), maintenance 400 mg/day (15 days)	Standard of care, oseltamivir (if needed)	18+	97	97	oropharyngeal swab	Yes	Yes	Y
Cavalcanti, 2020 [16]	Brazil	Hospital	HCQ	800 mg/day (7 days)	Standard of care	18+	221	227	oropharyngeal swab	Yes	Yes	Y
Chen, 2020[17]	China (Taiwan)	Hospital	HCQ	800 mg (1 day), maintenance 400 mg/day (6 days)	Standard of care	18+	19	11	oropharyngeal swab	Yes	Yes	Y
Lyngbakken, 2020 [18]	Norway	Hospital	HCQ	400 mg/day for 7 days	Standard of care	18+	26	25	oropharyngeal swab	Yes	No	Y
Pan, 2020 [19]	WHO (30 countries)	Hospital	HCQ	800 mg (1 day), 800 mg after 6 h, maintenance 800 mg/day (10 days)	Standard of care	18+	954	906	Any	Yes	No	Y
RECOVERY, 2020 [20]	UK	Hospital	HCQ	1600 mg/day, 800 mg/day (for 10 days) or discharge	Standard of care	Any	1,561	3,155	oropharyngeal swab	Yes	Yes	Y
Self, 2020 [21]	USA	Hospital Non-Hospital	HCQ	800mg (1 day), maintenance 400mg/day (4 days)	Placebo	18+	242	237	oropharyngeal swab	Yes	Yes	Y
Skipper, 2020 [22]	USA Canada	Non-hospital	HCQ	800mg + 600mg (1 day), maintenance 600mg/day (4 days)	Placebo	18+	244	247	oropharyngeal swab, or symptoms and exposure	Yes	Yes	N
Tang, 2020 [23]	China	Hospital	HCQ	1200mg/d (3 days), maintenance 800mg/day	Standard of care	18+	75	75	oropharyngeal sample	Yes	Yes	Y

WHO: World Health Organization; UK: United Kingdom; USA: United States of America; HCQ: hydroxychloroquine.

Table 2: Summary of findings table

Summary of findings:

**Hydroxychloroquine compared to standard of care for patients with COVID-19**

**Patient or population:** patients with COVID-19  
**Setting:** Hospital / outpatient clinic  
**Intervention:** Hydroxychloroquine  
**Comparison:** standard of care

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	N of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with standard of care	Risk with Hydroxychloroquine				
Mortality	185 per 1,000	<b>202 per 1,000</b> (183 to 220)	<b>RR 1.09</b> (0.99 to 1.19)	8303 (9 RCTs)	⊕⊕○○ LOW a,b	The evidence suggests that hydroxychloroquine results in little to no difference in mortality.
Serious adverse events	29 per 1,000	<b>35 per 1,000</b> (22 to 57)	<b>RR 1.22</b> (0.76 to 1.96)	6242 (6 RCTs)	⊕○○○ VERY LOW a,b,c,d	The evidence is very uncertain about the effect of hydroxychloroquine on severe adverse events.

\*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio

**GRADE Working Group grades of evidence**

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect  
**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different  
**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect  
**Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

**Explanations**

- a. Issues regarding allocation concealment and incomplete data (attrition bias).
- b. Treatment protocols, such as drug dosage and duration differed among trials. Participants combined in-hospital and outpatient use of HCQ.
- c. Issues regarding to allocation concealment and incomplete data (attrition bias). Criteria for determining adverse effects differed among trials.
- d. Wider confidence interval demonstrates either small benefit or very serious harm.

# Figures




Figure 1  
Flowchart of the assessed studies.





Figure 2  
Summarized and individual risk of bias assessment of the included studies.




Figure 3

Forest plot demonstrating no effect of hydroxychloroquine on mortality reduction (RR=1.09; 95% CI 0.99 – 1.19). M-H: Mantel-Haenszel.




Figure 4

Forest plot demonstrating no impact of hydroxychloroquine on serious adverse events (RR=1.22; 95%CI 0.76 – 1.96). M-H: Mantel-Haenszel.




Figure 5

Funnel plots evaluating publication bias for mortality (A) and serious adverse events (B) analyses.